600223 Stock Overview
Engages in the production and sales of pharmaceuticals, raw materials, and additives in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Lushang Freda Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.86 |
| 52 Week High | CN¥10.69 |
| 52 Week Low | CN¥5.74 |
| Beta | 1.8 |
| 11 Month Change | -5.12% |
| 3 Month Change | 13.39% |
| 1 Year Change | -33.91% |
| 33 Year Change | -52.29% |
| 5 Year Change | n/a |
| Change since IPO | -9.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600223 | CN Real Estate | CN Market | |
|---|---|---|---|
| 7D | 0.3% | -0.8% | -2.1% |
| 1Y | -33.9% | -5.5% | 2.8% |
Return vs Industry: 600223 underperformed the CN Real Estate industry which returned -5.5% over the past year.
Return vs Market: 600223 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 600223 volatility | |
|---|---|
| 600223 Average Weekly Movement | 6.1% |
| Real Estate Industry Average Movement | 8.2% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600223 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600223's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 3,651 | n/a | www.lshfreda.com |
Lushang Freda Pharmaceutical Co.,Ltd. engages in the production and sales of pharmaceuticals, raw materials, and additives in China. The company is involved in cosmetics and medicine businesses.
Lushang Freda Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600223 fundamental statistics | |
|---|---|
| Market cap | CN¥6.97b |
| Earnings (TTM) | CN¥236.52m |
| Revenue (TTM) | CN¥3.99b |
29.5x
P/E Ratio1.7x
P/S RatioIs 600223 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600223 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.99b |
| Cost of Revenue | CN¥2.01b |
| Gross Profit | CN¥1.98b |
| Other Expenses | CN¥1.74b |
| Earnings | CN¥236.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 49.57% |
| Net Profit Margin | 5.93% |
| Debt/Equity Ratio | 9.6% |
How did 600223 perform over the long term?
See historical performance and comparison